Agenus (AGEN) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Agenus (AGEN) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 41.5% versus a loss of 28.9%. Over five years, AGEN leads with a -90.6% price change compared with -97.3% for SABS. Agenus is the larger company by market cap ($270.1 million vs $253.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | SABS |
|---|---|---|
| Share price | $5.97 | $2.81 |
| Market cap | $270.12M | $253.15M |
| 1-day change | -2.77% | -3.44% |
| YTD return | +90.13% | -24.87% |
| 1-year return | +41.47% | -28.86% |
| 5-year return | -90.58% | -97.32% |
| P/E ratio (TTM) | 25.96 | — |
| EPS (TTM) | $0.23 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $114.20M | $0 |
| Revenue growth (YoY) | +10.37% | -100.00% |
| Net income (latest FY) | $-3.08M | $13.27M |
| Gross margin | 99.11% | — |
| Operating margin | -17.66% | — |
| Net margin | -2.70% | — |
| 52-week high | $10.31 | $5.15 |
| 52-week low | $2.71 | $2.44 |
| Distance from 52-week high | -42.10% | -45.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +352.26% | +314.23% |
| Average volume | 905.17K | 633.60K |
| Shares outstanding | 45.25M | 90.09M |
| Employees | 81 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed SABS by 70.3 percentage points over the past year.
- Agenus grew revenue faster in its latest fiscal year (+10.37% vs -100.00%).
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
AGEN vs SABS FAQ
Which is bigger, Agenus or SAB Biotherapeutics?
Agenus (AGEN) is larger, with a market capitalization of $270.12M compared with $253.15M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, AGEN or SABS?
AGEN returned +41.47% over the past 12 months, compared with -28.86% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.